Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
about
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older PatientsIncidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
P2860
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@ast
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@en
type
label
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@ast
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@en
prefLabel
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@ast
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@en
P2093
P2860
P1433
P1476
Continuous Trastuzumab Therapy ...... Left Ventricular Dysfunction.
@en
P2093
Anne A Eaton
Betty Y Lung
Chau T Dang
Clifford A Hudis
Howard T Thaler
Jennifer E Liu
Nandini U Yadav
Richard M Steingart
P2860
P304
P356
10.1634/THEONCOLOGIST.2015-0125
P50
P577
2015-08-03T00:00:00Z